8 analysts have expressed a variety of opinions on Nurix Therapeutics (NASDAQ:NRIX) over the past quarter, offering a diverse set of opinions from bullish to bearish.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $32.25, a high estimate of $36.00, and a low estimate of $28.00. This upward trend is apparent, with the current average reflecting a 5.74% increase from the previous average price target of $30.50.

Deciphering Analyst Ratings: An In-Depth Analysis

The standing of Nurix Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Nurix Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on Nurix Therapeutics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Discovering Nurix Therapeutics: A Closer Look

Nurix Therapeutics's Financial Performance

Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.

Revenue Challenges: Nurix Therapeutics's revenue growth over 3 months faced difficulties. As of 31 August, 2024, the company experienced a decline of approximately -31.84%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: Nurix Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -388.91% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Nurix Therapeutics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -13.1%, the company may face hurdles in achieving optimal financial returns.

Return on Assets (ROA): Nurix Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -9.56%, the company may face hurdles in generating optimal returns from its assets.

Debt Management: Nurix Therapeutics's debt-to-equity ratio is below the industry average at 0.07, reflecting a lower dependency on debt financing and a more conservative financial approach.

How Are Analyst Ratings Determined?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.